Literature DB >> 17254791

Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation.

Mona A Maalouf1, Andrew J Wiemer, Craig H Kuder, Raymond J Hohl, David F Wiemer.   

Abstract

Geminal bisphosphonates can be used for a variety of purposes in human disease including reduction of bone resorption in osteoporosis, treatment of fractures associated with malignancies of the prostate, breast, and lung, and direct anticancer activity against bone marrow derived malignancies. Previous research led to identification of some novel isoprenoid bisphosphonates that inhibit geranylgeranyl pyrophosphate (GGPP) synthesis and diminish protein geranylgeranylation. Described here is the synthesis of fluorescent anthranilate analogues of the most active isoprenoid bisphosphonates and examine their ability to impact post-translational processing of the small GTPases Ras, Rap1a, and Rab6. Similar to their non-fluorescent counterparts, some of these fluorescent isoprenoid bisphosphonates diminish protein geranylgeranylation. Their biological activity and fluorescent character suggest that they may be useful in studies of bisphosphonate localization both in cultured cells and in whole organisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17254791     DOI: 10.1016/j.bmc.2007.01.002

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

1.  Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration.

Authors:  Amel Dudakovic; Huaxiang Tong; Raymond J Hohl
Journal:  Invest New Drugs       Date:  2010-05-18       Impact factor: 3.850

2.  Synthesis of the C(18)-C(34) fragment of amphidinolide C and the C(18)-C(29) fragment of amphidinolide F.

Authors:  Sudeshna Roy; Christopher D Spilling
Journal:  Org Lett       Date:  2010-10-28       Impact factor: 6.005

3.  Triazole-based inhibitors of geranylgeranyltransferase II.

Authors:  Xiang Zhou; Sara V Hartman; Ella J Born; Jacqueline P Smits; Sarah A Holstein; David F Wiemer
Journal:  Bioorg Med Chem Lett       Date:  2012-12-01       Impact factor: 2.823

Review 4.  Site-Specific PEGylation of Therapeutic Proteins.

Authors:  Jonathan K Dozier; Mark D Distefano
Journal:  Int J Mol Sci       Date:  2015-10-28       Impact factor: 5.923

5.  Regulation of the Notch-ATM-abl axis by geranylgeranyl diphosphate synthase inhibition.

Authors:  Sherry S Agabiti; Jin Li; Willie Dong; Michael M Poe; Andrew J Wiemer
Journal:  Cell Death Dis       Date:  2019-09-30       Impact factor: 8.469

6.  Engineering protein farnesyltransferase for enzymatic protein labeling applications.

Authors:  Jonathan K Dozier; Santoshkumar L Khatwani; James W Wollack; Yen-Chih Wang; Claudia Schmidt-Dannert; Mark D Distefano
Journal:  Bioconjug Chem       Date:  2014-07-02       Impact factor: 4.774

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.